What can we help you find?
Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.
Closing these gaps in care could improve access for those worse affected by HIV in developing countries.
HIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.
Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.
Pharmacy Times® interviewed James Krellenstein, co-Founder, PrEP4All Collaboration and Organizer, The COVID-19 Working Group, to discuss the development of PrEP for the COVID-19 pandemic.
As we consider the implications of the COVID-19 pandemic and the release of remdesivir, ICER’s expedited evaluation raises some questions related to value-based pricing evaluations.
Adverse events included self-limited nausea and diarrhea with no difference between the 2 groups.
Despite the rate of HIV infection in adolescents and young adults, a study found that PrEP awareness is limited.
A new report from PrEP4All Collaboration warned that current research efforts aimed at controlling the COVID-19 pandemic are missing an important area of research into PrEP.
Leronlimab has been granted 2 other Fast Track designations as a combination therapy with HAART for HIV and as a treatment for metastatic triple-negative breast cancer.
On April 24, the CDC published some considerations for clinical providers who are evaluating adolescents for treatment with PrEP.
The study sought to determine the role of HIV related medical mistrust, and willingness to use PrEP among black women in the United States.